BC Extra | Dec 10, 2019
Company News

Janssen pays $750M for XBiotech's dermatology candidate after positive Phase II data

After searching for a new candidate to add to its immuno-dermatology pipeline, Janssen Biotech Inc. will spend $750 up front to acquire bermekimab, a clinical anti-IL-1α antibody, from XBiotech Inc. The mAb is first being...
BC Innovations | Oct 8, 2019
Distillery Therapeutics

Inhibiting caspase-mediated pyroptosis for graft-versus-host disease

DISEASE CATEGORY: Transplant INDICATION: Graft-versus-host disease (GvHD) Inhibiting CASP4 or CASP5, the human homologs of murine pyroptosis activator CASP11, or the downstream mediators GSDMD and IL-1α could prevent GvHD in leukemia patients undergoing allogeneic hematopoietic...
BC Innovations | Feb 7, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting IL-1α or IL-6 could help treat HER2-positive breast cancer. In patient tumor samples, levels of IL-1α or IL-6 were associated with poor metastasis-free survival, and...
BC Week In Review | Sep 22, 2017
Clinical News

CHMP reiterates negative opinion on XBiotech's Hutruo

EMA's CHMP reiterated its May negative opinion regarding an MAA from XBiotech Inc. (NASDAQ:XBIT) for Hutruo (Xilonix, CV-18C3, T2-18C3, RA-18C3, MABp1, CA-18C3) to treat symptoms of advanced colorectal cancer, including cachexia, saying the data provided...
BC Week In Review | Jun 16, 2017
Clinical News

XBiotech discontinues Xilonix CRC trial

XBiotech Inc. (NASDAQ:XBIT) said it is discontinuing the Phase III XCITE trial of Xilonix (CV-18C3, T2-18C3, RA-18C3, MABp1, CA-18C3) to treat colorectal cancer in about 643 patients. An IDMC recommended the study's termination based on...
BC Extra | Jun 9, 2017
Clinical News

XBiotech sags after discontinuing Xilonix CRC study

XBiotech Inc. (NASDAQ:XBIT) plummeted $6.22 (66%) to $3.20 after it said it is discontinuing the Phase III XCITE trial of Xilonix to treat colorectal cancer (CRC). An IDMC recommended the study's termination based on an...
BC Week In Review | May 25, 2017
Clinical News

CHMP recommends against XBiotech's colorectal cancer candidate

EMA’s CHMP recommended against approval of an MAA from XBiotech Inc. (NASDAQ:XBIT) for Xilonix (Hutruo, CV-18C3, T2-18C3, RA-18C3, MABp1, CA-18C3) to treat symptoms of advanced colorectal cancer, including cachexia. CHMP cited lack of efficacy in...
BC Extra | May 19, 2017
Company News

CHMP backs approval of Veltassa, other candidates

On Friday, EMA's CHMP recommended approval of several therapies, including hyperkalemia drug Veltassa patiromer, psoriasis drug Kyntheum brodalumab and schizophrenia treatment Reagila cariprazine . The committee also issued a negative opinion for colorectal cancer candidate Xilonix...
BC Week In Review | Apr 28, 2017
Clinical News

Hutruo regulatory update

XBiotech said EMA issued a negative “trend” vote for the company's MAA for colorectal cancer candidate Hutruo. The company said the vote means it is unlikely EMA’s CHMP will recommend the candidate at its May...
BC Extra | Apr 21, 2017
Company News

XBiotech hammered after negative EMA vote

XBiotech Inc. (NASDAQ:XBIT) lost $6.79 (40%) to $10.23 on Friday after saying EMA issued a negative “trend” vote for the company's MAA for colorectal cancer candidate Hutruo ( Xilonix ). The company said the vote means...
Items per page:
1 - 10 of 31